BAXTER—PAGE 13
Baxter International Inc.
Key Product Line Sales—US/International
Period Ending September 30, 2004
(unaudited)
($ in millions) | Q3 2004 | Q3 2003 | % Growth | ||||||||||||||||||||||
US | International | Total | US | International | Total | US | International | Total | |||||||||||||||||
BioScience | |||||||||||||||||||||||||
Recombinants | $ | 153 | $ 188 | $ | 341 | $ | 154 | $ 137 | $ | 291 | (1% | ) | 38% | 17% | |||||||||||
Plasma Proteins1 | 135 | 119 | 254 | 116 | 135 | 251 | 16% | (12% | ) | 1% | |||||||||||||||
Antibody Therapy | 49 | 33 | 82 | 45 | 32 | 77 | 8% | 4% | 6% | ||||||||||||||||
Transfusion Therapies | 62 | 62 | 124 | 63 | 70 | 133 | (2% | ) | (11% | ) | (7% | ) | |||||||||||||
Other2 | 9 | 39 | 48 | 17 | 51 | 68 | (47% | ) | (24% | ) | (29% | ) | |||||||||||||
Total BioScience | $ | 408 | $ 441 | $ | 849 | $ | 395 | $ 425 | $ | 820 | 3% | 4% | 4% | ||||||||||||
Medication Delivery | |||||||||||||||||||||||||
IV Therapies3 | $ | 93 | $ 182 | $ | 275 | $ | 106 | $ 169 | $ | 275 | (12% | ) | 8% | 0% | |||||||||||
Drug Delivery | 136 | 50 | 186 | 132 | 43 | 175 | 3% | 15% | 6% | ||||||||||||||||
Electronic Infusion Systems | 178 | 49 | 227 | 150 | 46 | 196 | 19% | 7% | 16% | ||||||||||||||||
Anesthesia | 179 | 17 | 196 | 180 | 17 | 197 | (1% | ) | 1% | 0% | |||||||||||||||
Other4 | 7 | 95 | 102 | 7 | 95 | 102 | 0% | 0% | 0% | ||||||||||||||||
Total Medication Delivery5 | $ | 593 | $ 393 | $ | 986 | $ | 575 | $ 370 | $ | 945 | 3% | 6% | 4% | ||||||||||||
Renal | |||||||||||||||||||||||||
PD Therapy | $ | 65 | $ 296 | $ | 361 | $ | 64 | $ 275 | $ | 339 | 2% | 8% | 7% | ||||||||||||
HD Therapy | 36 | 87 | 123 | 29 | 78 | 107 | 24% | 12% | 15% | ||||||||||||||||
Other | 0 | 1 | 1 | 4 | 1 | 5 | (100% | ) | 0% | (80% | ) | ||||||||||||||
Total Renal | $ | 101 | $ 384 | $ | 485 | $ | 97 | $ 354 | $ | 451 | 4% | 8% | 8% | ||||||||||||
TOTAL BAXTER | $ | 1,102 | $1,218 | $ | 2,320 | $ | 1,067 | $1,149 | $ | 2,216 | 3% | 6% | 5% | ||||||||||||
1 | Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products. |
2 | Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal). |
3 | Principally includes intravenous solutions and nutritional products. |
4 | Principally includes oncology and other hospital-distributed products. |
5 | Sales of pain management products, which were previously included in Anesthesia, are now reported in Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change. |
Note: In August 2004, the company restated its previously issued financial statements for 2001 through 2003 and the first quarter of 2004. This information reflects the restatements. Refer to the company’s Form 10-K/A for the year ended December 31, 2003 and Forms 10-Q/A for the quarters ended March 31, 2004 and September 30, 2003 for further information.